companiesCompany
Alphamab Oncology
aka 康宁杰瑞
Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.
Overview
Envafolimab (Enweida) approved 2021; KN026 (HER2 biparatopic bispecific) in phase 3 gastric and breast cancer; JSKN003 and JSKN033 (subcutaneous PD-L1 plus HER2 ADC) in trials. Its single-domain antibody platform is the basis of the subcutaneous formulations.
Headquarters
Suzhou, CN
Scorecard
All companies#89of 680 companies, score 30
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +19
1 approved, 0 in phase 3, 0 earlier, 1 targets, 87 registry studies. Formula on the scorecards page.
Type
biotech · 9966.HK
Stage
Public
Website
Founded
2008
Pages like this
not linked directly; found by shared links- ProductAdebrelimab
Shares PD-L1 and the tag china.
- ProductSugemalimab
Shares PD-L1 and the tag china.
- CancerCancer of unknown primary (CUP)
Shares Envafolimab, HER2.
- TechnologyImmuno-PET